Fabio Rosa

Fábio Rosa holds a PhD in Biomedicine from Lund University (Sweden) and the University of Coimbra (Portugal). His work has redefined cell fate engineering in immuno-oncology by pioneering direct cellular reprogramming to generate dendritic cells from unrelated cell types. He demonstrated for the first time that cancer cells can be reprogrammed in vivo using viral gene delivery to acquire antigen-presenting function and trigger systemic antitumor immunity, establishing tumors as programmable substrates for immune activation. He co-founded Asgard Therapeutics, where he has served as Head of Research since 2021, leading the selection and pre-clinical validation of AT-108, a first-in-class in situ gene therapy for tumor-to–dendritic cell reprogramming. Alongside viral approaches, he now drives exploratory programs using viral and non-viral vector platforms to expand the therapeutic reach of in situ immune cell reprogramming.